Immunovant Inc

NASDAQ:IMVT  
49.85
+0.96 (+1.96%)
Earnings Announcements

Immunovant Reports Q2 Loss Per $0.25

Published: 11/12/2020 13:28 GMT
(IMVT) - Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020.
Q2 Loss per Share $0.25.
Q2 Earnings per Share Estimate $-0.34 -- Refinitiv Ibes Data (analyst estimates).
Plan to Report Results From Phase 2a Clinical Trial of Imvt-1401 in Warm Autoimmune Hemolytic Anemia in Q1 of Calendar Year 2021.
Immunovant - Plan to Report Results From Phase 2b Clinical Trial of Imvt-1401 in Patients With Thyroid Eye Disease in First Half of Calendar Year 2021.
Plan to Announce Three New Indications for Imvt-1401 by August 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.27

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.